Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 3
1984 3
1985 8
1986 5
1987 6
1988 20
1989 14
1990 55
1991 64
1992 54
1993 97
1994 93
1995 109
1996 115
1997 85
1998 120
1999 106
2000 104
2001 98
2002 86
2003 96
2004 108
2005 110
2006 122
2007 130
2008 98
2009 112
2010 153
2011 130
2012 143
2013 176
2014 153
2015 131
2016 86
2017 50
2018 43
2019 30
2020 44
2021 31
2022 16
2023 16
2024 26
2025 30
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,037 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, Li J, Sai K, Xi S, Ouyang H, Liu M, Li X, Li Z, Ni X, Cao X, Li C, Wu S, Du X, Su J, Xue X, Wang Y, Li G, Qin Z, Yang H, Zhou T, Liu J, Hu X, Wang J, Jiang X, Lin F, Zhang X, Ke C, Lv X, Lv Y, Hu W, Zeng J, Chen Z, Zhong S, Wang H, Chen Y, Zhang J, Li D, Mou Y, Chen Z. Guo C, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2253285. doi: 10.1001/jamanetworkopen.2022.53285. JAMA Netw Open. 2023. PMID: 36705923 Free PMC article. Clinical Trial.
IMPORTANCE: High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The add-on efficacy of interferon alfa is unclear for the treatment of HGG. OBJ …
IMPORTANCE: High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for …
Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis.
Kinouchi T, Sakamoto J, Tsukamoto T, Akaza H, Kubota Y, Ozono S, Kanetake H, Taguchi T, Kotake T; Immunotherapy Oncology Group for Renal Cell Carcinoma. Kinouchi T, et al. J Cancer Res Clin Oncol. 2006 Aug;132(8):499-504. doi: 10.1007/s00432-006-0095-7. Epub 2006 Apr 4. J Cancer Res Clin Oncol. 2006. PMID: 16586071 Free PMC article. Clinical Trial.
METHODS: Patients received 5 million units (MU) natural interferon-alpha per day, five times a week, or the 5 MU natural interferon-alpha regimen plus a daily oral cimetidine. ...One patient in each group did not receive any natural …
METHODS: Patients received 5 million units (MU) natural interferon-alpha per day, five times a week, or the 5 MU nat …
Natural interferon alfa as maintenance therapy for small cell lung cancer.
Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Holsti P, Kumpulainen E, Cantell K. Mattson K, et al. Eur J Cancer. 1992;28A(8-9):1387-91. doi: 10.1016/0959-8049(92)90526-8. Eur J Cancer. 1992. PMID: 1325176 Clinical Trial.
We performed a 3-armed phase III study between 1982 and 1990 to evaluate low dose natural interferon alfa (nIFN-alpha) as a maintenance therapy in small cell lung cancer (SCLC) following induction chemotherapy (CT) and consolidation radiotherapy (RT). ...
We performed a 3-armed phase III study between 1982 and 1990 to evaluate low dose natural interferon alfa (nIFN-alpha) …
The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses.
Ji Y, Le Bert N, Lai-Hung Wong G, Douglas MW, Lee A, Zhu C, Wang B, Lv J, Li D, Tan Y, Ma H, Chen J, Chen X, Zhu Q, Yuen MF, Bertoletti A. Ji Y, et al. Gastroenterology. 2025 Jul;169(1):136-149. doi: 10.1053/j.gastro.2025.02.016. Epub 2025 Mar 3. Gastroenterology. 2025. PMID: 40043858 Clinical Trial.
We conducted a phase 2a study treating CHB participants with nine 4-weekly doses of HBV-targeted siRNA elebsiran (BRII-835), either alone (n = 10) or in combination with a virus-like particle-based therapeutic vaccine (BRII-179) containing Pre-S1, Pre-S2, and S antigens, coadmini …
We conducted a phase 2a study treating CHB participants with nine 4-weekly doses of HBV-targeted siRNA elebsiran (BRII-835), either alone (n …
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial.
Zhong Z, Deng D, Gao Y, Bu Q, Dai L, Feng X, Tang C, Luo X, Wang Y, Zhou C, Su G, Yang P. Zhong Z, et al. Lancet Rheumatol. 2024 Nov;6(11):e780-e790. doi: 10.1016/S2665-9913(24)00194-2. Epub 2024 Sep 2. Lancet Rheumatol. 2024. PMID: 39236720 Clinical Trial.
The least-squares mean difference between interferon alfa-2a and adalimumab was 0.50 (-0.04 to 1.04), which did not meet non-inferiority criteria (p=0.034 for non-inferiority). The primary outcome did not differ substantially between interferon alfa-2a …
The least-squares mean difference between interferon alfa-2a and adalimumab was 0.50 (-0.04 to 1.04), which did not meet non-i …
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Westin J, et al. Br J Haematol. 1995 Mar;89(3):561-8. doi: 10.1111/j.1365-2141.1995.tb08364.x. Br J Haematol. 1995. PMID: 7734355 Clinical Trial.
This clinical trial was designed to investigate if maintenance therapy with alfa-interferon could prolong the plateau phase in patients with multiple myeloma. In addition, the tolerability of interferon treatment and its effect on survival were evaluated. ... …
This clinical trial was designed to investigate if maintenance therapy with alfa-interferon could prolong the plateau phase in …
Peds-C.
Hoofnagle JH. Hoofnagle JH. Hepatology. 2005 Mar;41(3):421. doi: 10.1002/hep.20609. Hepatology. 2005. PMID: 15723319 Clinical Trial. No abstract available.
Intralesional interferon alfa-2b for the treatment of genital warts.
Welander CE, Homesley HD, Smiles KA, Peets EA. Welander CE, et al. Am J Obstet Gynecol. 1990 Feb;162(2):348-54. doi: 10.1016/0002-9378(90)90383-i. Am J Obstet Gynecol. 1990. PMID: 2155531 Clinical Trial.
A randomized, double-blind, placebo-controlled study has been conducted, and intralesional interferon alfa-2b was tested in the treatment of genital warts. This study design was to give 1 million units interferon alfa-2b intralesionally into the base o …
A randomized, double-blind, placebo-controlled study has been conducted, and intralesional interferon alfa-2b was tested in th …
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group. González-Peralta RP, et al. Hepatology. 2005 Nov;42(5):1010-8. doi: 10.1002/hep.20884. Hepatology. 2005. PMID: 16250032 Clinical Trial.
We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial cohort of a phase 1 study and then subsequently used it, in combination with interfero …
We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We d …
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
Vecchi A, Rossi M, Tiezzi C, Fisicaro P, Doselli S, Gabor EA, Penna A, Montali I, Ceccatelli Berti C, Reverberi V, Montali A, Fletcher SP, Degasperi E, Sambarino D, Laccabue D, Facchetti F, Schivazappa S, Loggi E, Coco B, Cavallone D, Rosselli Del Turco E, Massari M, Pedrazzi G, Missale G, Verucchi G, Andreone P, Brunetto MR, Lampertico P, Ferrari C, Boni C. Vecchi A, et al. Gut. 2024 Sep 9;73(10):1737-1748. doi: 10.1136/gutjnl-2024-332290. Gut. 2024. PMID: 39033025 Free PMC article. Clinical Trial.
OBJECTIVE: Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-alpha) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-alpha on T and …
OBJECTIVE: Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon- …
3,037 results